Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    cholangiocarcinoma AND cisplatin/gemcitabine | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine;   Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
2 Recruiting Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
Conditions: Biliary Tract Cancer;   Gallbladder Cancer;   Cholangiocarcinoma;   Ampullary Cancer
Interventions: Other: Active Symptom Control;   Drug: L-folinic acid;   Drug: 5 FU;   Drug: Oxaliplatin
3 Recruiting 90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres);   Drug: Gemcitabine;   Drug: Cisplatin
4 Recruiting Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945;   Drug: Cisplatin;   Drug: Gemcitabine
5 Recruiting A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
Condition: Cholangiocarcinoma
Interventions: Drug: Amphinex and Gemcitabine;   Drug: Gemcitabine and Cisplatin
6 Recruiting Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Conditions: Biliary Carcinoma;   Gall Bladder Carcinoma;   Cholangiocarcinoma;   Gastrointestinal Tumor
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Copanlisib
7 Recruiting Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer
Conditions: Cholangiocarcinoma;   Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Other: Observation
8 Not yet recruiting Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Conditions: Non-Resectable Cholangiocarcinoma;   Recurrent Cholangiocarcinoma;   Stage III Extrahepatic Bile Duct Cancer;   Stage III Intrahepatic Cholangiocarcinoma;   Stage IIIA Hilar Cholangiocarcinoma;   Stage IIIB Hilar Cholangiocarcinoma;   Stage IVA Extrahepatic Bile Duct Cancer;   Stage IVA Hilar Cholangiocarcinoma;   Stage IVA Intrahepatic Cholangiocarcinoma;   Stage IVB Extrahepatic Bile Duct Cancer;   Stage IVB Hilar Cholangiocarcinoma;   Stage IVB Intrahepatic Cholangiocarcinoma;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ricolinostat
9 Not yet recruiting A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Conditions: Solid Tumor;   Breast Cancer;   Colon Cancer;   Cholangiocarcinoma;   Soft Tissue Sarcoma
Interventions: Drug: LY3039478;   Drug: Taladegib;   Drug: Abemaciclib;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: LY3023414
10 Recruiting Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Device: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo;   Drug: Gem-Cis or Gem-Carbo
11 Recruiting Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Radiation: High Dose Radiation;   Drug: Systemic chemotherapy
12 Recruiting Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Photodynamic therapy-Photofrin;   Procedure: Stenting procedure;   Drug: Chemotherapy regimen
13 Recruiting A Study of LY2801653 in Advanced Cancer
Condition: Cancer
Interventions: Drug: LY2801653;   Drug: Cetuximab;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Ramucirumab
14 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
15 Recruiting Treatment for Bile Duct Cancer in the Liver
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
16 Recruiting Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers
Condition: Biliary Tract Cancer
Interventions: Drug: Abraxane (Nab-Paclitaxel);   Drug: Cisplatin;   Drug: Gemcitabine;   Behavioral: Phone Calls
17 Recruiting Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: FOLFIRINOX
18 Recruiting Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Pancreatic Adenocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Gallbladder Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Biological: Recombinant EphB4-HSA Fusion Protein
19 Recruiting Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Conditions: Malignant Solid Tumour;   Carcinoma, Non-Small-Cell Lung;   Stomach Neoplasms;   Urothelial Carcinoma;   Endometrial Neoplasms;   Multiple Myeloma;   MPN;   Breast Cancer;   Cholangiocarcinoma
Interventions: Drug: INCB054828;   Drug: Gemcitabine+Cisplatin;   Drug: Pembrolizumab;   Drug: Docetaxel

Study has passed its completion date and status has not been verified in more than two years.